CBS 2019
CBSMD教育中心
English

科学研究

科研文章

荐读文献

Treatment and prevention of lipoprotein(a)-mediated cardiovascular disease: the emerging potential of RNA interference therapeutics Stent underexpansion and residual reference segment stenosis are related to stent thrombosis after sirolimus-eluting stent implantation: an intravascular ultrasound study Management of Asymptomatic Severe Aortic Stenosis: Evolving Concepts in Timing of Valve Replacement Transcatheter Aortic Valve Replacement in Patients With Multivalvular Heart Disease Glycemic Index, Glycemic Load, and Cardiovascular Disease and Mortality Cardiac surgery following transcatheter aortic valve replacement Determinants and Impact of Heart Failure Readmission Following Transcatheter Aortic Valve Replacement New-onset atrial fibrillation after PCI and CABG for left main disease: insights from the EXCEL trial and additional studies Long-Term All-Cause and Cause-Specific Mortality in Asymptomatic Patients With CAC ≥1,000: Results From the CAC Consortium Impact of Incomplete Coronary Revascularization on Late Ischemic and Bleeding Events after Transcatheter Aortic Valve Replacement
|<<... 122 123 124 125 126 127 128 ...>>|

Original Research2020 Dec 16;e13473.

JOURNAL：Eur J Clin Invest . Article Link

Initial experience with percutaneous mitral valve repair in patients with cardiac amyloidosis

MJ Volz, ST Pleger, A Weber et al. Keywords: PMVR; amyloid cardiomyopathy; cardiac amyloidosis; mitral regurgitation

ABSTRACT

BACKGROUND - Percutaneous mitral valve repair (PMVR) is a therapeutic option for severe mitral regurgitation (MR) in patients with heart failure due to differential etiologies. However, only little is known about the safety and efficacy of this procedure in patients with amyloid cardiomyopathy.


METHODS - Five Patients with cardiac amyloidosis and moderate to severe or severe MR undergoing PMVR were analyzed retrospectively and compared to seven patients with cardiac amyloidosis and severe MR without intervention. Clinical and functional data, renal function and cardiac biomarkers as well as established risk scores for cardiac amyloidosis were assessed. Primary endpoint was the reduction in MR one year after PMVR. Secondary endpoints were safety, overall mortality after 12 months compared to the control group, as well as changes in clinical and functional parameters.


RESULTS - Amyloidosis risk assessment documented amyloid cardiomyopathy at an advanced stage in all patients. Procedural, technical and device success of PMVR were all 100% and residual MR remained mild to moderate at 12 months follow‐up (p=0.038 vs. before PMVR). Differences in survival compared to the control (no PMVR) group pointed to a possible survival benefit in the PMVR group (p= 0.02).


CONCLUSION - PMVR is a feasible and safe procedure in patients with cardiac amyloidosis and might carry a possible survival benefit in this patient group.

 



>CBS CBS 2019

> CBS 2019

> CBS 2019 注册

> CBS 2019 会议日程

> CBS 2019 学术征集

> CBS 2019 热点

 CBSMD

> CBSMD 网站注册

> 教育中心

> 荐读文献

> Top 10 阅读文献

> 文献导读
CBS 2019 CBS 2019 主席团 教育中心 科研动态
Copyright ⓒ CBS MD Nanjing China. All rights reserved. 京ICP备16025898号-11
联系我们| Top